Indigenous mRNA Covid-19 vaccine candidate, Gennova Biopharmaceuticals’ HGCO19, has got approval to start phase-2 and 3 clinical trials in the country.

If things go according to plan, the vaccine would be available in the market by the end of this year, sources said.

The Pune-based biotech firm submitted interim clinical data of the phase-1 study to the Central Drugs Standard Control Organisation (CDSCO).…

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study.

"Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the…

Gennova Biopharmaceuticals Ltd., the Pune-based biotechnology company, working on the nation’s first mRNA-based COVID-19 vaccine, submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India’s National Regulatory Authority (NRA).

Vaccine Subject Expert Committee (SEC) reviewed the interim Phase I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.…

In a significant development towards India’s vaccination efforts, the Drug Controller General of India, has approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals (Gennova).

Gennova, the subsidiary of Pune based Emcure Pharmaceuticals Limited had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India's National…

India’s first COVID-19 mRNA vaccine has been given the go-ahead from the Director Controller General of India to move into the phase 2/3 clinical trials as it has been found safe.

Gennova Biopharmaceuticals Ltd., (an Emcure group of companies), a Pune-based biotechnology company that has been working on the nation’s first mRNA-based COVID-19 vaccine, The Indian Express (TIE) reported.…

DGCI gave a green nod to Gennova Biopharmaceuticals Ltd's COVID-19 vaccine. This is India's first indigenously developed mRNA vaccine. The Gennova Biopharmaceuticals is a part of the Emcure group of companies and is based in Pune. The biotechnology company has been working on the nation’s first mRNA-based Covid-19 vaccine, since last year and has cleared the safety protocols in the first phase of trials.…

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study.

"Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the…

Gennova Biopharmaceuticals Ltd (GBL), the Pune-based biotechnology company working on the nation’s first mRNA-based Covid-19 vaccine submitted the interim clinical data of the Phase-I study to the Central Drugs Standard Control Organisation (CDSCO), the union government’s National Regulatory Authority (NRA).

Vaccine Subject Expert Committee (SEC) reviewed the interim phase-I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study, the Union…

The Covid-19 vaccine of Indian pharmaceutical firm Gennova Biopharmaceuticals, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said.

Government authorities have also approved further studies to test the vaccine’s efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India.…

India has approved further clinical trials for its first homegrown mRNA-based COVID-19 vaccine developed by Gennova Biopharmaceuticals Ltd, the government said on Tuesday, after the shot was found to be safe and effective in an early-stage study.

Gennova is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to…

The Indian Women’s Health Report 2021 surveying 1,000 working women aged between 25 and 55 across seven cities has revealed that around half of them are not comfortable talking about one or more health issues due to the prevalent societal taboo and stigmas associated with them.
https://indianexpress.com/article/cities/pune/working-women-health-issues-7499063/

Kolkata, Sep 08 (UNI) The Indian Women’s Health Report 2021 surveying 1000 working women aged between 25 to 55 years across seven cities has revealed that around half of the women surveyed are not comfortable talking about one or more women’s health issues due to the prevalent societal taboo and stigmas associated with them.…

The Indian Women’s Health Report 2021 surveying 1000 working women aged between 25 to 55 years across seven cities has revealed that around half of the women surveyed are not comfortable talking about one or more women’s health issues due to the prevalent societal taboo and stigmas associated with them.

The study has been conducted by Emcure Pharmaceuticals in association with Ipsos Research Private Limited (Ipsos India) with an objective to gain insights on the social, cultural and…

At a time when female workforce participation is dropping to a new low at the national level, the discrimination being faced by women over their health is high. A report, titled ‘Indian Women’s Health Report 2021,’ compiled by Emcure Pharmaceuticals, has found that a whopping 71 per cent of women in Hyderabad said that their male colleagues lacked sensitivity towards women-related health issues.…

The mRNA-based vaccine has been developed in partnership with Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC).

•Gennova Biopharmaceuticals Ltd., which is a Pune-based biotechnology company, had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO) and the Centre's National Regulatory Authority (NRA).

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study.

"Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the…

Pune-based Emcure Pharmaceuticals has come forth again to publicly list its shares on exchanges.

In 2014, the company had attempted to hit the stock exchanges, but reportedly did not pursue it after Bain Capital invested about ₹226 crore, by which it was able to meet its immediate liquidity needs…

Talking about health-related issues continues to remain a stigma for working women in white-collar jobs across major urban cities including Hyderabad, a survey ‘Indian Women’s Health Report 2021’ taken-up by Emcure Pharmaceuticals said.

The pharma company conducted a survey of 1,000 working women aged between 25 years and 55 years in white-collar jobs across seven cities including Hyderabad, Bengaluru, Chennai, Delhi, Kolkata, Mumbai and Pune.…

‘The Indian Women’s Health Report 2021’ a study by Emcure Pharmaceuticals that surveyed working women of 25 to 55 years in white-collar jobs across 7 cities (Bangalore, Chennai, Delhi, Hyderabad, Kolkata, Mumbai and Pune) reveals prevalent societal stigma prevents most women from talking about their health-related issues

86% of the working women have observed their colleagues/relatives/friends drop out of the workforce, 59% of whom cited health issues as the main reason.

80% of the…

The Indian Women’s Health Report 2021 surveying 1,000 working women aged between 25 and 55 years, across seven cities, has revealed that about half the women surveyed were not comfortable talking about one or more women’s health issues due to the prevalent societal taboo and stigma associated with them.…